ReviewJournal of anesthesia2026
The current status and future perspectives of transfusion products in Japan.
Review in Journal of anesthesia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In reply to the article by Park et al. on expanding the transfusion paradigm toward sustainable transfusion strategies.Journal of anesthesia · 2026Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Japan, Ministry of Health, Labour and Welfare statistics show a significant decline in blood donors from 1985 to 2023, especially among young people and high school students, while donations among those aged 50 - 69 increased substantially. The decline has been attributed in part to reduced promotional activities. According to the material in the Japanese Red Cross Society, the production and supply volume of red blood cells (RBCs) and platelet concentrates (PCs) remained stable from 2006 to 2023, whereas the supply of fresh frozen plasma (FFP) has decreased. The 2003 Act on Securing a Stable Supply of Safe Blood Products requires medical physicians to ensure appropriate use of blood products. In cases of massive hemorrhage, however, appropriate use for life-saving transfusion is required. The new 2025 Guideline for the Management of Critical Bleeding introduced recommendations on cryoprecipitate and fibrinogen use, and added guidance on tranexamic acid, calcium supplementation, and sodium bicarbonate. To reduce transfusion in routine clinical practice, autologous transfusion should also be considered. In 2024, the Blood Donation Promotion Committee emphasized the importance of research to develop new products.
Indexed as
Identifiers
41366601What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.